xenleta
nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - antibakterielle midler til systemisk brug, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..
ovugel
vetoquinol - triptorelin acetate - hypofysiske og hypotalamiske hormoner og analoger - pigs (sows for reproduction) - for the synchronisation of ovulation in weaned sows to enable a single fixed-time artificial insemination.
icatibant accord
accord healthcare s.l.u. - icatibant acetate - angioødemer, arvelige - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.
ganirelix gedeon richter
chemical works of gedeon richter plc. (gedeon richter plc.) - ganirelix acetate - reproductive techniques, assisted; ovulation induction; infertility, female - hypofysiske og hypotalamiske hormoner og analoger - prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation (coh) for assisted reproduction techniques (art).
mycapssa
amryt pharmaceuticals dac - octreotide acetate - akromegali - hypofysiske og hypotalamiske hormoner og analoger - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatiske neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
cisordinol-acutard 50 mg/ml injektionsvæske, opløsning
h. lundbeck a/s - zuclopenthixolacetat - injektionsvæske, opløsning - 50 mg/ml
clopixol-acuphase 50 mg/ml injektionsvæske, opløsning
2care4 aps - zuclopenthixolacetat - injektionsvæske, opløsning - 50 mg/ml
zuclopenthixolacetat orifarm 50 mg/ml injektionsvæske, opløsning
orifarm a/s - zuclopenthixolacetat - injektionsvæske, opløsning - 50 mg/ml
clopixol-acuphase 50 mg/ml injektionsvæske, opløsning
orifarm a/s - zuclopenthixolacetat - injektionsvæske, opløsning - 50 mg/ml